NDA 204384 · Janssen Therap
Sirturo
Bedaquiline Fumarate · Oral
NovelAccelerated approvalPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Jul 28, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2012
Dec 28, 2012
Approved uses
5
Original approval plus efficacy supplements
Registered trials
92
30 Phase 3, 15 recruiting
FAERS reports
1,441
1,379 serious, 341 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: QTc PROLONGATION QTc prolongation can occur with SIRTURO. Use with drugs that prolong the QTc interval may cause additive QTc prolongation. Monitor ECGs. Discontinue SIRTURO if significant ventricular arrhythmia or QTc interval greater than 500 ms develops [see Warnings and Precautions (5.1) ] . WARNING: QTc PROLONGATION See full prescribing information for complete boxed warning. QTc Prolongation QTc prolongation can occur with SIRTURO. Use with drugs that prolong the QTc interval may cause additive QTc prolongation. Monitor ECGs. Discontinue SIRTURO if significant ventricular arrhythmia or QTc interval greater than 500 ms develops. ( 5.1 )
What it is approved for
From the label in effect Oct 17, 2025.
SIRTURO is a diarylquinoline antimycobacterial drug indicated as part of combination therapy in the treatment of adult and pediatric patients (2 years and older and weighing at least 8 kg) with pulmonary tuberculosis (TB) due to Mycobacterium tuberculosis resistant to at least rifampin and isoniazid. SIRTURO is a diarylquinoline antimycobacterial drug indicated as part of combination therapy in adult and pediatric patients (2 years and older and weighing at least 8 kg) with pulmonary tuberculosis (TB) due to Mycobacterium tuberculosis resistant to at least rifampin and isoniazid. ( 1 ) Limitations of Use : Do not use SIRTURO for the treatment of latent, extra-pulmonary or drug-sensitive TB or for the treatment of infections caused by non-tuberculous mycobacteria. ( 1 ) Limitations of Use Do not use SIRTURO for the treatment of: Latent infection due to Mycobacterium tuberculosis ( M. tuberculosis ) Drug-sensitive pulmonary TB Extra-pulmonary TB Infections caused by non-tuberculous mycobacteria
Mechanism: Bedaquiline is a diarylquinoline antimycobacterial drug [see Microbiology (12.4) ] .
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jul 28, 2025 Supplement 20 · Efficacy · priority review OrphanLabelMedication GuideLetter
- Jun 21, 2024 Supplement 19 · Efficacy OrphanLabelLetter
- May 27, 2020 Supplement 13 · Efficacy · priority review OrphanLabelLetter
- Aug 9, 2019 Supplement 10 · Efficacy OrphanLabelLetter
- Dec 28, 2012 Original approval · Type 1 - New Molecular Entity · priority review NovelAccelerated approvalOrphanLabelReviewSummary Review
2 products under this application
- SIRTURO · BEDAQUILINE FUMARATE EQ 100MG BASE · TABLET, ORAL · Prescription
- SIRTURO · BEDAQUILINE FUMARATE EQ 20MG BASE · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Bedaquiline" as an intervention, any sponsor and status, largest first.
- Bedaquiline Enhanced Post ExpOsure Prophylaxis for LeprosyPivotal-lookingRecruiting
Institute of Tropical Medicine, BelgiumAcademic, hospital or other
NCT05597280 · 124,000 participants (planned) · Start Mar 22, 2023 · Primary completion Mar 15, 2027
Drug: BE-PEP Bedaquiline; SDR-PEP Rifampicin and 1 more · For: Leprosy
Sites: Moroni, Comoros
- Bedaquiline Roll-out Evidence in Contacts and People Living With HIV to Prevent TBPivotal-lookingRecruiting
Johns Hopkins UniversityAcademic, hospital or other
NCT06568484 · 2,530 participants (planned) · Start May 8, 2026 · Primary completion Jul 2027
Drug: Bedaquiline; Levofloxacin · For: Tuberculosis, Latent
Sites: Ulaanbaatar, Mongolia; Lima, Peru; Mbeya, Tanzania · 8 sites in all
- Platform Assessing Regimens and Durations In a Global Multisite Consortium for TBPivotal-lookingRecruiting
University College, LondonAcademic, hospital or other
NCT06114628 · 2,500 participants (planned) · Start Jan 9, 2024 · Primary completion Feb 24, 2027
Drug: Ganfeborole; BTZ-043 and 11 more · For: Pulmonary Tuberculosis
Sites: Chisinau, Moldova; Cape Town, South Africa; George, South Africa · 11 sites in all
- Evaluating Newly Approved Drugs for Multidrug-resistant TBPivotal-lookingCompleted
Médecins Sans Frontières, FranceAcademic, hospital or other
NCT02754765 · 754 participants · Start Dec 2016 · Primary completion Jun 2023
Drug: Bedaquiline; Delamanid and 6 more · For: Tuberculosis, Multidrug-Resistant; Infection, Bacterial; Pulmonary Tuberculoses
Sites: Tbilisi, Georgia; Pune, India; Almaty, Kazakhstan · 12 sites in all
- Two-month Regimens Using Novel Combinations to Augment Treatment Effectiveness for Drug-sensitive TuberculosisPivotal-lookingCompleted
University College, LondonAcademic, hospital or other
NCT03474198 · 675 participants · Start Mar 21, 2018 · Primary completion Jan 20, 2022
Drug: Rifampicin; Isoniazid and 8 more · For: Tuberculosis, Pulmonary
Sites: New Delhi, India; Bandung, Indonesia; Jakarta, Indonesia · 18 sites in all
- A PAN-USR TB Multi-Center TrialPivotal-lookingRecruiting
Shenzhen Third People's HospitalAcademic, hospital or other
NCT06905522 · 610 participants (planned) · Start Jun 18, 2025 · Primary completion Jan 2029
Drug: Bedaquiline (B); Sitafloxacin (S) and 7 more · For: Pulmonary Tuberculosis
Sites: Beijing, China; Shenzhen, China; Ürümqi, China
- The Evaluation of a Standard Treatment Regimen of Anti-tuberculosis Drugs for Patients With MDR-TBPivotal-lookingCompleted
IUATLD, IncAcademic, hospital or other
NCT02409290 · 588 participants · Start Mar 2016 · Primary completion May 13, 2022
Drug: Regimen A locally-used WHO-approved MDR-TB regimen (2011 guideline); Moxifloxacin and 8 more · For: MDR-TB
Sites: Addis Ababa, Ethiopia; Tbilisi, Georgia; Ahmedabad, India · 13 sites in all
- Pragmatic Clinical Trial for a More Effective Concise and Less Toxic MDR-TB Treatment Regimen(s)Pivotal-lookingCompleted
Medecins Sans Frontieres, NetherlandsAcademic, hospital or other
NCT02589782 · 552 participants · Start Jan 2017 · Primary completion Aug 5, 2022
Drug: Bedaquiline; Pretomanid and 4 more · For: Tuberculosis, Multidrug-Resistant; Extensively Drug-Resistant Tuberculosis; Tuberculosis, Pulmonary
Sites: Minsk, Belarus; Johannesburg, South Africa; Durban, South Africa · 7 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- electrocardiogram qt prolonged223
- off label use174
- hepatotoxicity149
- anaemia146
- neuropathy peripheral109
- nausea93
- death73
- intentional product use issue72
- vomiting72
- decreased appetite46
- dyspnoea46
- dizziness44
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2014 | 1 |
| 2015 | 21 |
| 2016 | 32 |
| 2017 | 74 |
| 2018 | 199 |
| 2019 | 266 |
| 2020 | 155 |
| 2021 | 77 |
| 2022 | 193 |
| 2023 | 145 |
| 2024 | 119 |
| 2025 | 102 |
| 2026 | 57 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Sirturo (Bedaquiline Fumarate)
2024 spending
$2.8M
Beneficiaries
103
637 claims
Per beneficiary
$27,341
$159.10 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $1,579,345 |
| 2021 | $2,041,547 |
| 2022 | $2,147,056 |
| 2023 | $3,019,486 |
| 2024 | $2,816,094 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Oral Regimens for Rifampin-Resistant, Fluoroquinolone-Susceptible Tuberculosis.
Guglielmetti L, Khan U, Velásquez GE, et al. · N Engl J Med 2025 · Clinical Trial, Phase III, Comparative Study
- Treatment of Highly Drug-Resistant Pulmonary Tuberculosis.
Conradie F, Diacon AH, Ngubane N, et al. · N Engl J Med 2020 · Clinical Trial, Research Support, Non-U.S. Gov't
- Bedaquiline-Pretomanid-Linezolid Regimens for Drug-Resistant Tuberculosis.
Conradie F, Bagdasaryan TR, Borisov S, et al. · N Engl J Med 2022 · Randomized Controlled Trial
- Treatment Strategy for Rifampin-Susceptible Tuberculosis.
Paton NI, Cousins C, Suresh C, et al. · N Engl J Med 2023 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis.
Nyang'wa BT, Berry C, Kazounis E, et al. · N Engl J Med 2022 · Clinical Trial, Phase II, Clinical Trial, Phase III
- Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis.
Lan Z, Ahmad N, Baghaei P, et al. · Lancet Respir Med 2020 · Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
Sponsor: Johnson & Johnson (Janssen)
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.